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Amyloidosis, characterized by the  deposition of extracellular material exhibiting green 
birefringence under the  polarized microscope after Congo red staining and thin, rigid, 
nonbranching fibrillar profiles by electron microscopy, can occur de novo {primary), in 
relation  to  chronic  inflammatory  or  infectious  diseases  (secondary)  or  tumors  (i.e. 
myeloma), and is now known to be far more widespread than previously believed (1,  2). 
The nature of amyloid has  become increasingly clear, and recent amino acid sequence 
analyses have shown primary and myeloma amyloid to consist of a protein homologous to 
the variable portion of immunoglobulin  light chain and secondary amyloid to be a unique 
nonimmunoglobulin  protein (A-protein) (3, 4). Nevertheless, the pathogenesis of amyloid 
remains  unsolved  and  effective  methods  for  prevention  and  treatment  are  not  yet 
established  (1-4).  Attempts  to  prevent the  occurrence of amyloidosis in experimental 
animal models using a  variety of treatments including anti-inflammatory, immunosup- 
pressive, and anticarcinogenic  treatments have not been consistently effective, or indeed 
have accelerated amyloid induction under certain circumstances (2, 5, 6). 
We  report  here  our  experimental  data  in  a  "casein-induced"  mouse  amyloid 
model which demonstrate that amyloid induction can be successfully blocked by 
the administration  of colchicine, not only when colchicine is given for the entire 
course of the amyloid induction regimen but, more significantly, when it is given 
only  in  the  late  pre-amyloid  and  the  amyloid  phase  of the  regimen  or to the 
recipients  after "transfer of amyloid (2)." 
Materials  and Methods 
Animals.  Animals used in the present study were 6 8-wk old  female  CBA/J  mice  (Jackson 
Laboratories,  Bar Harbor, Maine) and were maintained on Purina Chow pellets {Ralston Purina Co., 
St. Louis, Mo.) and water ad libitum. 
Standard  Amyloid Induction.  Mice were given daily subcutaneous injections of 0.5 ml of 10% 
casein solution (7) and sacrificed on the day after the last injection. 
Colchicine Administration.  Colchicine (as "colchicine  injection," Eli Lilly & Co., Indianapolis, 
Ind.) was diluted with physiological saline to make a final concentration 0.05 mg/ml, and injected 
intraperitoneally into mice. 
Amyloid Induction by "Trans[er of  Amyloid."  Amyloidosis has been shown to be "transferred" in 
several ways (2). The necessary duration for amyloid induction can be significantly reduced  in the 
recipients by the injection  of tissue (especially spleen) homogenate or extracts from the animals in the 
late pre-amyloid or the amyloid phase  of the amyloid induction regimen.  With this "transfer of 
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amyloid" experiment, various side effects of the amyloid induction regimen in the early phases, which 
may not be directly related to amyloid production, can probably be eliminated from the recipients. In 
the present study, donor mice received nine daily casein injections and were sacrificed on the day 
after the last  injection. Spleens were removed and homogenized thoroughly in cold physiological 
saline  with  a  Potter-Elvehjem homogenizer (Potter  Instrument  Co.,  Inc.,  Melville,  N.  Y.).  By 
examination of frozen sections after Congo red staining, none of the spleens demonstrated amyloid 
deposition, so that the mice were judged to be in the late pre-amyloid phase of the amyloid induction 
regimen. The spleen homogenate was frozen and thawed, and then injected intraperitoneally to the 
recipients at  a  rate of one donor spleen to one recipient. The recipients received six daily casein 
injections commencing on the same day of the "transfer," and were sacrificed on the day after the 
last casein injection. 
Evaluation  of Results.  Spleens, livers, and kidneys were examined for amyloid deposition by 
light and electron microscopy (7). 
Results 
As our accumulated data indicate (7, 8) and as confirmed by the present control 
study (Exp.  1,  2,  and  11 in Table I), our standard  amyloid induction  schedule 
TABLE I 
Effects of Colchicine on Amyloid Induction  in Mouse Model 
No. of casein 
Exp. no. 
inj.* 
Incidence of  Colchicine$  No. of mice 
amyloid 
Total 
Daily dose  No...°f  Splenic  Hepatic  mice 
mj.  amyloid  amyloid  used 
Spleen  Liver 
mg  % 
Standard amyloid induction 
1  0  0  0  0  0  12  0  0 
2  14  0  0  10  0  12  83  0 
3  14  0.005  14  2  0  10  20  0 
4  14  0.010  14  0  0  8  0  0 
5  14  0.015  14  0  0  9  0  0 
6  14  0.005  6  3  0  10  30  0 
7  14  0.010  6  1  0  9  11  0 
8  14  0.015  6  0  0  10  0  0 
9  14  0.020  6  0  0  10  0  0 
10  14  0.025  6  0  0  7  0  0 
11  21  0  0  9  8  9  100  89 
12  21  0.015  13  0  0  12  0  0 
13  21  0.020  13  0  0  7  0  0 
14  21  0.015  7  8  1  9  89  11 
"Transfer of amyloid" induction§ 
15  6  0  0  10  7  10  100  70 
16  6  0.015  6  0  0  10  0  0 
17  6  0.020  6  0  0  8  0  0 
* Daily subcutaneous injection of 0.5 ml of 10% casein solution. 
Colchicine was intraperitoneally injected concurrently with casein for the entire course or the last 
days of the casein injections. 
§ Spleen homogenate from donor mice which had received nine casein injections was intraperito- 
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onto  CBA/J  mice  usually  induces  amyloid  in  the  spleen  after  12-18  casein 
injections,  in  the  liver  after  16-22  injections  and  in  the  kidney  after  20-26 
injections.  For  example,  none  develops  amyloid  after  eight  casein  injections, 
70-90% of the animals have splenic amyloid after 14 injections (Fig. 1), and after 
21  injections  amyloid is found  in all spleens and 80-90% of the livers. 
Preliminary  study  showed  that  daily  injections  of  more  than  0.025  mg  of 
colchicine  were lethal--all  animals  died within  7  days.  With  0.020  mg per day, 
the mice survived for 5-15 days. Most of the mice tolerated daily injections of less 
than 0.015  mg colchicine  (up to 21  injections). 
When  the  casein  and  the  colchicine  injections  were  given  concurrently,  the 
FIG.  1.  Light  micrograph  of a  mouse spleen  after 14 daily  casein  injections  without  col- 
chicine.  Amyloid, which stains well with  Congo red  and demonstrates  green birefringence 
under the polarized light, deposits in the marginal zone (arrows). F, lymph follicle. Congo red 
and hematoxylin stain. × 80. 
FIG.  2  Mouse spleen  after  14  daily  casein  injections  and  6 daily  injections  of 0.015 mg 
colchicine starting on the 9th day of the casein injection schedule; comparable  area to that 
shown in Fig. 1. No amyloid is demonstrable.  F, lymph follicle. Congo red and hematoxylin 
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incidence  of  amyloidosis  was  significantly  decreased  or  completely blocked 
depending upon the dosage of colchicine. For example, 14 daily casein injections 
accompanied by 14 daily injections of 0.005 mg colchicine induced amyloidosis in 
only  2  out  of  10  animals.  None  of the  mice  receiving  more than  0.010  mg 
colchicine per day along with casein developed amyloid (Exp. 3-5 in Table I). 
Moreover, the colchicine injectons at the late pre-amyloid or the amyloid phase 
of the  amyloid  induction  regimen,  which  is  considered  to  relate  directly to 
amyloid formation  (2,  6),  were  found  to  be  equally  effective (Table  I).  For 
example, six daily injections of 0.005-0.010 mg colchicine started on the 9th day 
of the 14 casein injection schedule (late pre-amyloid phase) reduced significantly 
the incidence of amyloidosis (Exp. 6 and 7 in Table I), and with more than 0.015 
mg colchicine, the amyloid induction was prevented completely (Exp. 8-10 in 
Table I) (Fig. 2). Daily injections of high doses of colchicine starting with the late 
pre-amyloid phase (on the 9th day) prevented amyloid induction even when the 
casein injections were extended to 21  days (Exp.  12 and 13 in Table I). When 
seven colchicine injections were given during the last days of 21 casein injections, 
i.e.  commencing on  the  15th  day  of the  casein  injections  (amyloid  phase), 
deposition of amyloid was found in 89% of spleens and in 11% of livers (Exp. 14 in 
Table  I),  suggesting that  additional  amyloid deposition was  inhibited by the 
colchicine administration  after the  15th  day of the casein  injection schedule, 
though amyloid which had already deposited may not have been significantly 
absorbed during the colchicine treatment. 
With  the  "transfer  of  amyloid"  followed  by  six  daily  casein  injections, 
amyloidosis was induced in all the recipients (Exp. 15 in Table I). However, when 
daily doses of 0.015-0.020 mg of colchicine were administered concurrently with 
the casein, none of the recipients developed amyloidosis (Exp. 16 and 17 in Table 
I). 
Discussion 
Despite  considerable  efforts  made  by  a  number  of  investigators,  effective 
methods  for  prevention  and  treatment  of  amyloidosis  have  not  yet  been 
established either clinically or experimentally (1,  2). A few treatments appar- 
ently effective in  inhibiting amyloid induction in experimental animal models 
depended on their application  in  the early pre-amyloid phase  of the amyloid 
induction regimen (6).  Various treatments  applied to  the animals  in  the late 
pre-amyloid or the amyloid phase of standard amyloid induction regimen or to 
the recipients after the "transfer of amyloid" were always found either to be 
inconsistently effective or to accelerate amyloid induction (2, 5, 6). 
The present results demonstrate that colchicine inhibits amyloid induction in 
the experimental mouse model, not only when it is given for the entire course of 
the amyloid induction regimen but also when it is administered only at the late 
pre-amyloid phase,  at  the  amyloid phase  or after the  "transfer of amyloid." 
Moreover,  the  data  suggest  that  colchicine is  probably  effective in  blocking 
amyloidogenesis  at  its  final  stage(s).  Colchicine  may,  however,  not  affect 
significantly amyloid already deposited in the tissue. 1106  SHIRAHAMA  AND  COHEN  BRIEF  DEFINITIVE REPORT 
Although the pathogenesis of amyloid is not yet clear, there is a large body of 
evidence indicating that the reticuloendothelial cells play an important role in its 
formation  (2,  6,  8).  Colchicine,  widely  used  clinically,  is  known  to  disrupt 
microtubules  (including  neurotubules)  in  vivo  and  in  vitro  or  inhibit  their 
assemblage through its specific binding to the protein subunit, "tubulin". It also 
has  a  strong effect on  endocytosis including "reverse endocytosis" (9,  10).  No 
available data indicate that colchicine has a significant effect on the biosynthesis 
of proteins and other substances. One may speculate that colchicine inhibits the 
endocytic activity of the reticuloendothelial cells and eventually affects amyloid 
fibril formation, or, as a remote possibility, it binds with amyloid fibril subunits 
and prohibits their polymerization. 
Finally, the present observation is of importance since (a)  it may lead to the 
establishment of effective methods for the prevention and treatment of amyloido- 
sis, (b) this method for blocking amyloid production in experimental animals will 
be helpful for further exploration of the mechanism of amyloidogenesis, and (c) 
the system will contribute toward further clarification of the biological effects of 
colchicine. 
Summary 
Colchicine was found to have a strong inhibitory effect on amyloid induction in 
an animal model. When CBA/J mice were treated with colchicine concurrently 
with the amyloid induction regimen, the incidence of amyloidosis was, depending 
upon the dosage of colchicine, significantly decreased (0.005-0.010 mg colchicine 
per  day) or completely blocked (more than 0.015  mg colchicine per day). The 
colchicine treatment was effective not only when colchicine was given for the 
entire course of the amyloid induction regimen but also when it was given only in 
the late pre-amyloid or the amyloid phase of the regimen or to the recipients after 
the transfer of amyloid. The data suggest the colchicine is effective in blocking 
amyloidogenesis at its final stage(s), while it may not affect significantly amyloid 
already deposited in the tissue. 
Received for publication 8 July 1974. 
Note added in proof.  While this paper was in press, the following studies were brought 
to our attention at the International Symposium on Amyloidosis held on August 26-28, 
1974 at Helsinki, Finland. E. Sohar and J. Gafni presented  data on the familial Mediter- 
ranean fever with colchicine and its possible preventive  effect on amyloidosis (N. Engl. 
J. Med. In press) and the prophylactic effect of colchicine on experimental  murine amy- 
loidosis was also independently observed (Kedar (Keizman), I., M. Rabid, E. Sohar, and 
J. Gafni. 1974. Israel J. Med. Sci.  10:787). 
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